This CME program is derived from content presented at the Advanced Curriculum for Multiple Sclerosis 2025 CME/CE Course. The expert faculty, Dr. Benjamin Greenberg, will review first Bruton's tyrosine kinase (BTK) therapeutics for the management of patients with multiple sclerosis. Following, he will discuss how to develop treatment plans to address the unmet needs of patients with secondary progressive MS. Lastly, Dr. Greenberg will analyze clinical trial data for BTK therapeutics to manage patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Neurologists, MS specialists, pharmacists, APPs, nurses, and other healthcare professionals involved in the management of patients with multiple sclerosis
Review BTK therapeutics for the management of patients with MS.
Develop treatment plans to address the unmet needs of patients with secondary progressive MS.
Review and analyze clinical trial data for BTK therapeutics to manage patients with nrSPMS.
Review of the Management of Patients with Progressive MS
Brain Penetrant BTK Therapeutics
The Potential Impact of BTK Therapeutics on the Long-Term Care of Patients with Secondary MS
| Faculty | Relationship Identified With: |
| Benjamin Greenberg, MD | Consultant/Advisor: Amgen Inc.; Arialys Therapeutics; Clene Inc.; EMD Serono Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GenrAb; IQVIA; Novartis AG; Regeneron Pharmaceuticals Inc.; Sandoz AG; Sanofi Genzyme; Signant Health; Syneos Health; TG Therapeutics Grant/Research Support: Anokion Equity Holder: Clene Inc.; GenrAb |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Sanofi.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sanofi do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606
